JP2010511018A5 - - Google Patents

Download PDF

Info

Publication number
JP2010511018A5
JP2010511018A5 JP2009538725A JP2009538725A JP2010511018A5 JP 2010511018 A5 JP2010511018 A5 JP 2010511018A5 JP 2009538725 A JP2009538725 A JP 2009538725A JP 2009538725 A JP2009538725 A JP 2009538725A JP 2010511018 A5 JP2010511018 A5 JP 2010511018A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
alkyl
compound
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009538725A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010511018A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2007/063106 external-priority patent/WO2008065198A1/en
Publication of JP2010511018A publication Critical patent/JP2010511018A/ja
Publication of JP2010511018A5 publication Critical patent/JP2010511018A5/ja
Pending legal-status Critical Current

Links

JP2009538725A 2006-12-01 2007-11-30 変性疾患及び炎症性疾患の治療に有用なトリアゾロピリジン化合物 Pending JP2010511018A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86814406P 2006-12-01 2006-12-01
PCT/EP2007/063106 WO2008065198A1 (en) 2006-12-01 2007-11-30 Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases

Publications (2)

Publication Number Publication Date
JP2010511018A JP2010511018A (ja) 2010-04-08
JP2010511018A5 true JP2010511018A5 (enExample) 2010-11-25

Family

ID=38983774

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009538725A Pending JP2010511018A (ja) 2006-12-01 2007-11-30 変性疾患及び炎症性疾患の治療に有用なトリアゾロピリジン化合物

Country Status (6)

Country Link
US (1) US7977352B2 (enExample)
EP (1) EP2086540B8 (enExample)
JP (1) JP2010511018A (enExample)
AT (1) ATE495743T1 (enExample)
DE (1) DE602007012133D1 (enExample)
WO (1) WO2008065198A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0907892A2 (pt) 2008-02-20 2015-07-28 Actelion Pharmaceuticals Ltd Composto antibiótico azatricíclico, medicamento, composição farmacêutica que o contém e uso do mesmo
EP2254887B9 (en) 2008-02-22 2013-05-29 Actelion Pharmaceuticals Ltd. Oxazolidinone derivatives
JO3041B1 (ar) * 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
BRPI0920895A8 (pt) 2008-10-07 2017-12-26 Actelion Pharmaceuticals Ltd Compostos antibióticos de oxazolidinona tricíclica
KR101667066B1 (ko) 2008-10-10 2016-10-17 액테리온 파마슈티칼 리미티드 옥사졸리디닐 항생제
CN102459258B (zh) 2009-06-05 2015-11-25 赛福伦公司 1,2,4-三唑并[1,5a]吡啶衍生物的制备和用途
JP2011168582A (ja) * 2010-01-21 2011-09-01 Ishihara Sangyo Kaisha Ltd トリアゾロピリジン誘導体又はその塩、それらの製造方法及びそれらを含有する有害生物防除剤
MX2016002764A (es) 2013-09-05 2016-05-26 Hoffmann La Roche Compuestos de triazolopiridina, composiciones y metodos de uso de los mismos.
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
TW201613860A (en) 2014-02-13 2016-04-16 Incyte Corp Cyclopropylamines as LSD1 inhibitors
PL3105218T3 (pl) 2014-02-13 2020-03-31 Incyte Corporation Cyklopropyloaminy jako inhibitory lsd1
LT3105226T (lt) 2014-02-13 2019-11-11 Incyte Corp Ciklopropilaminai, kaip lsd1 inhibitoriai
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為lsd1抑制劑之咪唑并吡啶及咪唑并吡嗪
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
KR102710120B1 (ko) 2015-08-12 2024-09-27 인사이트 홀딩스 코포레이션 Lsd1 저해제의 염
WO2017184934A1 (en) 2016-04-22 2017-10-26 Incyte Corporation Formulations of an lsd1 inhibitor
US10815231B2 (en) 2016-06-29 2020-10-27 West China Hospital, Sichuan University [1,2,4] triazolo [1,5-a] pyridine derivative and crystalline form thereof
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
CA3031675A1 (en) 2016-07-30 2018-02-08 Bristol-Myers Squibb Company Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors
WO2018049089A1 (en) 2016-09-09 2018-03-15 Bristol-Myers Squibb Company Pyridyl substituted indole compounds
JP7117293B2 (ja) 2016-09-16 2022-08-12 ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト (ゲーエムベーハー) Traf6阻害剤
KR102651947B1 (ko) 2017-08-04 2024-03-26 브리스톨-마이어스 스큅 컴퍼니 Tlr7/8/9의 억제제로서 유용한 치환된 인돌 화합물
CN110997670B (zh) 2017-08-04 2022-11-01 百时美施贵宝公司 [1,2,4]三唑并[4,3-a]吡啶基取代的吲哚化合物
KR102849449B1 (ko) 2017-11-14 2025-08-21 브리스톨-마이어스 스큅 컴퍼니 치환된 인돌 화합물
CA3085333A1 (en) 2017-12-15 2019-06-20 Bristol-Myers Squibb Company Substituted indole ether compounds
TWI689510B (zh) 2017-12-18 2020-04-01 美商必治妥美雅史谷比公司 4-氮雜吲哚化合物
ES2977657T3 (es) 2017-12-19 2024-08-28 Bristol Myers Squibb Co Compuestos de 6-azaindol
JP7313354B2 (ja) 2017-12-19 2023-07-24 ブリストル-マイヤーズ スクイブ カンパニー Tlr阻害剤として有用なアミド置換されたインドール化合物
US11878975B2 (en) 2017-12-19 2024-01-23 Bristol-Myers Squibb Company Substituted indole compounds useful as TLR inhibitors
ES2904773T3 (es) 2017-12-20 2022-04-06 Bristol Myers Squibb Co Compuestos de diazaindol
CN111491918B (zh) 2017-12-20 2023-10-24 百时美施贵宝公司 芳基和杂芳基取代的吲哚化合物
MX2020005513A (es) 2017-12-20 2020-09-03 Bristol Myers Squibb Co Compuestos de amino indol utiles como inhibidores de receptores tipo toll (tlr).
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
WO2020086505A1 (en) 2018-10-24 2020-04-30 Bristol-Myers Squibb Company Substituted indole dimer compounds
JP7597709B2 (ja) 2018-10-24 2024-12-10 ブリストル-マイヤーズ スクイブ カンパニー 置換インドールおよびインダゾール化合物
CN114126713B (zh) 2019-05-09 2023-12-08 百时美施贵宝公司 经取代的苯并咪唑酮化合物
US12448395B2 (en) 2019-10-01 2025-10-21 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
ES2965164T3 (es) 2019-10-04 2024-04-11 Bristol Myers Squibb Co Compuestos de carbazol sustituidos
WO2022081967A1 (en) * 2020-10-16 2022-04-21 Rheos Medicines, Inc. Malt1 modulators and uses thereof
WO2025042408A1 (en) * 2023-08-18 2025-02-27 Schrödinger, Inc. Methods of treating cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
WO2004014908A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
EP1543008B1 (en) 2002-09-23 2007-11-07 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
US7576085B2 (en) * 2002-09-23 2009-08-18 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
US20080033006A1 (en) 2004-01-26 2008-02-07 Altana Pharma Ag 1,2,4-Triazolo[ 1,5-A] Pyridines as Gastric Acid Secretion Inhibitors
US20050288502A1 (en) * 2004-06-25 2005-12-29 Andersen Denise L Substituted heterocyclic compounds and methods of use
TW200804386A (en) 2005-11-10 2008-01-16 Schering Corp Imidazopyrazines as protein kinase inhibitors
US7893058B2 (en) 2006-05-15 2011-02-22 Janssen Pharmaceutica Nv Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
PT2029602E (pt) 2006-05-31 2010-07-08 Galapagos Nv Compostos de triazolopirazina uteis para o tratamento de doenãas degenerativas e inflamatërias
JP2010511019A (ja) 2006-12-01 2010-04-08 ガラパゴス・ナムローゼ・フェンノートシャップ 変性疾患及び炎症性疾患の治療に有用なイミダゾロピリジン化合物

Similar Documents

Publication Publication Date Title
JP2010511018A5 (enExample)
JP2010511019A5 (enExample)
RU2403258C2 (ru) Тиазолилдигидроиндазолы
JP2020169171A5 (enExample)
RU2442778C9 (ru) Новые соединения, действующие как ингибиторы erk
RU2350605C2 (ru) Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ
RU2007109870A (ru) 2,4-ди(аминофенил)пиримидины в качестве ингибиторов plk-киназ
RU2016150486A (ru) Ингибиторы бета-лактамазы
JP2008510691A5 (enExample)
RU2008152087A (ru) Макроциклические оксимильные ингибиторы протеазы гепатита
CN112955454A (zh) 作为Wee1抑制剂的嘧啶并吡唑酮类衍生物及其应用
JP2017508789A5 (enExample)
JP2013532652A5 (enExample)
CA2394327A1 (en) Substituted piperazine and piperidine calcium channel blockers
RU2011133128A (ru) Противоопухолевые соединения дигидропиран-2-она
JP2014509647A5 (enExample)
JP2019522055A5 (enExample)
JP2012505871A5 (enExample)
RU2013108348A (ru) Конденсированные гетероарилы и их применение
RU2019116590A (ru) Трициклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич
RU2013109415A (ru) Способы ингибирования фукозилирования белков in vivo с использованием аналогов фукозы
RU2006116628A (ru) Новые производные имидазола и их применение в качестве фармацевтических агентов
JP2017519754A5 (enExample)
JP2008506644A5 (enExample)
RU2006135541A (ru) Производные аминокислот